Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid

AIDS

Volumn 14, Issue 13, 2000, Pages 1949-1954

  Cunningham, Philip H ^a   Smith, Danielle G ^a   Satchell, Claudette ^a   Cooper, David A ^a,b   Brew, Bruce ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Brain; Cerebrospinal fluid; HIV drug resistance; Neurological; Resistance mutations; Reverse transcriptase inhibitors

Indexed keywords

DIDANOSINE; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; DRUG RESISTANCE; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PLASMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AIDS DEMENTIA COMPLEX; ANTI-HIV AGENTS; CEREBROSPINAL FLUID; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0034622946     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200009080-00010     Document Type: Article

References (21)

1. Dementia in AIDS patients: Incidence and risk factors
2. Zidovudine for the treatment of AIDS dementia complex: Results of a placebo-controlled trial
3. Concurrent evolution of regions of the envelope and polymerase genes of human immunodeficiency virus type 1 observed during zidovudine (AZT) therapy
4. In vivo compartmentalization of human immunodeficiency virus; evidence from the examination of pol sequences from autopsy tissue
5. Syncytium-inducing phenotype and zidovudine susceptibility of HIV-1 isolated from post-mortem tissue
6. The relationship between AIDS dementia complex and the presence of macrophage tropic and non-syncytium inducing isolates of human immunodeficiency virus virus type 1 in the cerebrospinal fluid
7. In-vivo comparison of zidovudine resitance mutations in blood and CSF of HIV-1 infected patients
8. Zidovudine-resistant variants of HIV-1 in brain
9. Neurological disorders during HIV-1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype
10. Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients
11. In-vivo evidence of HIV-1 productive infection in cerebrospinal fluid of patients with HIV-1 encephalitis
12. Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage
13. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection
14. Central nervous system as a sanctuary for HIV-1 infection despite treatment with zidovudine, lamivudine and indinavir
15. Concentrations of CSF proteins as a measure of blood brain barrier function and IgG synthesis within the CNS in 'normal' subjects from the age of 6 months to 30 years
16. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene
17. Preventing HIV-1 drug resistance
18. Genetic polymorphism near HIV-1 reverse transcriptase resistance-associated codons is a major obstacle for the line probe assay as an alternative method to sequence analysis
19. Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes
20. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome
21. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain